drugset
drugset / Trial / NCT01289899

Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects

NCT01289899 ↗

Phase 1 Completed 16 enrolled Boryung Pharmaceutical Co., Ltd Covance · collab
RandomizedParallel-groupDouble-blind

Summary

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.

Timeline

Start
2004-01
Primary completion
2004-02
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FIMASARTAN POTASSIUM TRIHYDRATE Unknown 120 mg Oral
Subject FIMASARTAN POTASSIUM TRIHYDRATE Unknown 360 mg Oral

Indications

essential hypertension